Persistence of Clinically Significant Portal Hypertension After Eradication of Hepatitis C Virus in Patients With Advanced Cirrhosis
Cristina Díez, Juan Berenguer, Luis Ibáñez, Elba Llop, Leire Pérez‐Latorre, María Vega Catalina, Víctor Hontañón, María Ángeles Jiménez‐Sousa, Teresa Aldámiz‐Echevarría, Javier Martínez, José Luís Calleja, Agustı́n Albillos, José M. Bellón, Salvador Resino, Juan González‐García, Rafael Bañares
Abstract
This prospective study of 34 patients with HCV cirrhosis (17 HIV positive) with baseline clinically significant portal hypertension (CSPH; HVPG ≥10 mmHg) and SVR after DAA therapy showed that disappearance of CSPH (primary endpoint) is a rare event (6/18 patients; 18%), indicating a persistent risk of clinical progression or death.
Topics & Concepts
MedicinePortal hypertensionCirrhosisClinical endpointInternal medicineHepatitis C virusGastroenterologyPersistence (discontinuity)Hepatitis CPortal venous pressureVirusImmunologyClinical trialGeotechnical engineeringEngineeringLiver Disease and TransplantationLiver Disease Diagnosis and TreatmentHepatitis C virus research